April 21, 2026
3 min watch
In this video, Ursula A. Matulonis, MD, discusses results from the phase 3 ROSELLA trial, which assessed the combination of relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer.
The data, presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, showed statistically significant improvements in PFS and OS among patients randomly assigned relacorilant (Lifyorli, Corcept Therapeutics) plus nab-paclitaxel (Abraxane, Bristol Myers Squibb) vs. nab-paclitaxel alone.
“This trial led to the full FDA approval of relacorilant and Abraxane for patients with platinum-resistant ovarian cancer [after] up to three prior lines [of treatment] and definitely is an option for our patients,” Matulonis, chief of the division of gynecologic oncology at Dana-Farber Cancer Institute, said.
For more information:
Ursula A. Matulonis, MD, can be reached at ursula_matulonis@dfci.harvard.edu.
Sources/Disclosures
Source:
Healio Interviews
Reference:
- Olawaiye AB, et al. Final overall survival results from the phase 3 ROSELLA trial: Relacorilant plus nab-paclitaxel vs. nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer. Presented at: Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; April 10-13, 2026; San Juan, Puerto Rico.
Disclosures:
Healio could not determine relevant financial disclosures at the time of publication.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
<
Leave a Reply